Clinical Trials Logo

Clinical Trial Summary

To determine if administration of levalbuterol tartrate HFA MDI in subjects with EIB will be effective in the prevention of EIB and be safe and well-tolerated.


Clinical Trial Description

This was a randomized, double-blind, placebo-controlled, multicenter, two-way crossover study of levalbuterol tartrate HFA MDI in subjects 18 years of age and older with EIB. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00268723
Study type Interventional
Source Sunovion
Contact
Status Completed
Phase Phase 3
Start date December 2005
Completion date February 2006

See also
  Status Clinical Trial Phase
Withdrawn NCT00375232 - Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes N/A
Completed NCT00085774 - Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma Phase 3
Withdrawn NCT03610932 - Vitamin C & Exercise Induced Bronchoconstriction (EIB) N/A
Withdrawn NCT00662779 - Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB) Phase 3
Completed NCT00701025 - Mechanisms of Exercise-induced Bronchospasm